Log in or Sign up for Free to view tailored content for your specialty!
Kidney Care Community News
Results show benefits of drug to treat primary hyperoxaluria type 1 in young children
Phase 3 results from the Illuminate-B study suggest lumasiran, an investigational RNA interference therapeutic, may be safe and effective for treating pediatric patients who have primary hyperoxaluria type 1.
Midlife obesity shows varying impacts on kidney disease risk based on sex, race
Researchers from Johns Hopkins found both Black and white women who were obese at midlife had increased risks for eGFR decline and end-stage kidney disease after 30 years of follow-up.
Log in or Sign up for Free to view tailored content for your specialty!
Younger kidney donors lead to better chance of graft survival
The association of donor-recipient size mismatch on long-term graft survival is influenced greatly by recipient and donor age, according to findings from a recently published study.
Education program increases staff knowledge of peritoneal dialysis
After a peritoneal dialysis education program, the number of staff at a Veterans Affairs center who scored their knowledge level on the topic as “high” and “very high” increased, according to presented research.
Canagliflozin most effective in higher-risk patients for cardiovascular, kidney outcomes
Using the Kidney Disease: Improving Global Outcomes criteria, researchers found patients with type 2 diabetes who were at higher risk for adverse cardiovascular and kidney outcomes reaped the most benefits from canagliflozin.
Randomized clinical trial participation does not impact dialysis facility quality scores
Patients meet clinical quality targets equally at dialysis facilities that participate vs. centers that do not participate in randomized clinical trials, according to presented research.
Outset Medical raises $277 million in Wall Street debut
With the closing of its initial public offering of 10,293,777 shares of common stock last week, dialysis machine manufacturer Outset Medical Inc. has raised $277.9 million, the company announced.
CMS finalizes ESRD Treatment Choices model, estimates $23 million in savings
CMS released the final version of its ESRD Treatment Choices payment model today, aimed at incentivizing dialysis providers to place more patients with end-stage renal disease on home dialysis or refer them for a kidney transplant.
FDA approves new drug application for phosphorus drug
Ardelyx Inc. recently announced the FDA has accepted its new drug application of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
Belimumab plus standard therapy superior to standard therapy alone for lupus nephritis
A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New England Journal of Medicine.
-
Headline News
Severe carbohydrate restriction not necessary for ketosis, weight loss in low-energy diets
November 25, 20242 min read -
Headline News
Triple-digit heat exposure may increase odds of atrial fibrillation
November 16, 20242 min read -
Headline News
Vaccine using live-attenuated malaria parasites shows promise
November 25, 20242 min read
-
Headline News
Severe carbohydrate restriction not necessary for ketosis, weight loss in low-energy diets
November 25, 20242 min read -
Headline News
Triple-digit heat exposure may increase odds of atrial fibrillation
November 16, 20242 min read -
Headline News
Vaccine using live-attenuated malaria parasites shows promise
November 25, 20242 min read